Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Irinotecan and Cetuximab on an Every 2 Week Schedule, as Second Line Therapy in Patients With Advanced Colorectal Cancer

NCT00336856 is registered in ClinicalTrials.gov with University of Pittsburgh as lead sponsor.

NCT NCT00336856
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00336856 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Irinotecan and Cetuximab on an Every 2 Week Schedule, as Second Line Therapy in Patients With Advanced Colorectal Cancer
Lead sponsor
University of Pittsburgh
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2006
Completion date
June 30, 2011
Enrollment
35 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colon cancer, rectum cancer